Literature DB >> 28258497

Treatment of pediatric-onset lupus nephritis: a proposal of optimal therapy.

Hiroshi Tanaka1,2, Kensuke Joh3, Tadaatsu Imaizumi4.   

Abstract

Lupus nephritis (LN) is one of the major clinical manifestations of systemic lupus erythematosus (SLE) which occurs frequently in the early stages of pediatric-onset cases. Since SLE is a chronic disease associated with frequent disease flares and effective and safe maintenance therapy is required for achieving a favorable outcome, optimal treatment for LN in pubertal patients is a great challenge that remains to be overcome. Although its etiology remains unclear, it has been reported that the innate and adaptive immune systems have been reported to play an important role in the pathogenesis of SLE. However, studies of drugs that have been useful in controlling inflammatory pathways mediated by the innate and adaptive immune systems are now underway. In clinical practice, recent advances in the management of LN, together with earlier renal biopsy and selective use of aggressive immunosuppressive therapy, have contributed to a favorable outcome in children and adolescents with LN. However, the balance of the efficacy of treatment in terms of long-term prognosis and its adverse effects should be weighed in determining the treatment strategy.

Entities:  

Keywords:  Immunosuppressive treatment; Lupus nephritis; Mizoribine; Multitarget therapy; Pediatric-onset; Systemic lupus erythematosus; Tacrolimus

Mesh:

Substances:

Year:  2017        PMID: 28258497     DOI: 10.1007/s10157-017-1381-1

Source DB:  PubMed          Journal:  Clin Exp Nephrol        ISSN: 1342-1751            Impact factor:   2.801


  48 in total

1.  Single dose of rituximab for pediatric-onset refractory systemic lupus erythematosus.

Authors:  F Ikeda; S Watanabe; T Aizawa-Yashiro; K Tsuruga; E Ito; H Tanaka
Journal:  Lupus       Date:  2013-08-21       Impact factor: 2.911

2.  Chloroquine attenuates TLR3/IFN-β signaling in cultured normal human mesangial cells: A possible protective effect against renal damage in lupus nephritis.

Authors:  Tadaatsu Imaizumi; Ryo Hayakari; Tomoh Matsumiya; Hidemi Yoshida; Kazushi Tsuruga; Shojiro Watanabe; Shogo Kawaguchi; Hiroshi Tanaka
Journal:  Mod Rheumatol       Date:  2017-02-21       Impact factor: 3.023

3.  Therapeutic drug monitoring of mycophenolate mofetil for the treatment of severely active lupus nephritis.

Authors:  W Kittanamongkolchai; C Rukrung; T Supasiri; I Lertjirachai; P Somparn; P Chariyavilaskul; Y Avihingsanon
Journal:  Lupus       Date:  2013-05-07       Impact factor: 2.911

4.  Initial presentation of childhood-onset systemic lupus erythematosus: a French multicenter study.

Authors:  B Bader-Meunier; J B Armengaud; E Haddad; R Salomon; G Deschênes; I Koné-Paut; T Leblanc; C Loirat; P Niaudet; J C Piette; A M Prieur; P Quartier; F Bouissou; M Foulard; G Leverger; I Lemelle; P Pilet; M Rodière; N Sirvent; P Cochat
Journal:  J Pediatr       Date:  2005-05       Impact factor: 4.406

5.  The outcome of patients with renal involvement in pediatric-onset systemic lupus erythematosus--a 20-year experience in Asia.

Authors:  P-Y Lee; K-W Yeh; T-C Yao; W-I Lee; Y-J Lin; J-L Huang
Journal:  Lupus       Date:  2013-08-21       Impact factor: 2.911

Review 6.  The pathogenesis, diagnosis and treatment of lupus nephritis.

Authors:  Noa Schwartz; Beatrice Goilav; Chaim Putterman
Journal:  Curr Opin Rheumatol       Date:  2014-09       Impact factor: 5.006

7.  Interferon-Stimulated Gene 15, a Type I Interferon-Dependent Transcript, Is Involved in a Negative Feedback Loop in Innate Immune Reactions in Human Mesangial Cells.

Authors:  Tadaatsu Imaizumi; Taku Shimada; Tomoh Matsumiya; Hidemi Yoshida; Shojiro Watanabe; Kazushi Tsuruga; Shogo Kawaguchi; Manabu Murakami; Kensuke Joh; Hiroshi Tanaka
Journal:  Nephron       Date:  2016-02-05       Impact factor: 2.847

8.  Practice patterns and approach to kidney biopsy in lupus: a collaboration of the Midwest Pediatric Nephrology Consortium and the Childhood Arthritis and Rheumatology Research Alliance.

Authors:  Scott E Wenderfer; Jerome C Lane; Ibrahim F Shatat; Emily von Scheven; Natasha M Ruth
Journal:  Pediatr Rheumatol Online J       Date:  2015-06-19       Impact factor: 3.054

9.  Mizoribine intermittent pulse protocol for induction therapy for systemic lupus erythematosus in children: an open-label pilot study with five newly diagnosed patients.

Authors:  Hiroshi Tanaka; Koji Tsugawa; Eishin Oki; Koichi Suzuki; Etsuro Ito
Journal:  Clin Rheumatol       Date:  2007-05-05       Impact factor: 3.650

10.  Intravenous cyclophosphamide combined with steroids in pediatric onset severe lupus nephritis.

Authors:  Prayong Vachvanichsanong; Pornsak Dissaneewate; Edward McNeil
Journal:  Int Urol Nephrol       Date:  2012-12-07       Impact factor: 2.370

View more
  3 in total

Review 1.  Off-label use of tacrolimus in children with glomerular disease: Effectiveness, safety and pharmacokinetics.

Authors:  Guo-Xiang Hao; Lin-Lin Song; Dong-Feng Zhang; Le-Qun Su; Evelyne Jacqz-Aigrain; Wei Zhao
Journal:  Br J Clin Pharmacol       Date:  2020-01-14       Impact factor: 4.335

2.  Efficacy and safety of tacrolimus in induction therapy of patients with lupus nephritis.

Authors:  Tianbiao Zhou; Shujun Lin; Shen Yang; Wenshan Lin
Journal:  Drug Des Devel Ther       Date:  2019-03-12       Impact factor: 4.162

3.  Combination of tacrolimus and mycophenolate mofetil in persistent proteinuria due to refractory childhood lupus nephritis.

Authors:  Abdulaziz Almutairi; Ziyad Alkathiri; Sulaiman M Al-Mayouf
Journal:  Int J Pediatr Adolesc Med       Date:  2018-08-09
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.